Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | Management of cold agglutinin disease

Sigbjorn Berentsen, MD, PhD, Haugesund Hospital, Haugesund, Norway, provides an overview of the current treatment landscape for cold agglutinin disease (CAD). Due to a previous lack of effective treatments, patients with mild cases of CAD were left untreated and with the arrival of novel therapies, a higher number of patients will benefit from treatment. The current recommended treatments include rituximab and bendamustine, with rituximab monotherapy being a suitable alternative in frail patients. Complement-targeted therapeutics are also a substitute to current regimens, but only treat symptoms relating to hemolytic anemia. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.